Injectable Contraceptives Match Oral Contraceptives in Incidence of Female Cancers

Share this article:

An article published on March 7 in PLoS Medicine revealed that women who use injectable contraceptives increased their risk of developing certain female cancers. The cancer risks associated with the use of oral contraceptives were known prior to this study; the cancer risks of injectable contraceptive use were unknown.

The study, which was conducted and published by Dr. Margaret Urban and her global peers, analyzed epidemiological case-control data obtained from a South African hospital. Data compared self-reported contraceptive use (oral and injectable) in black South African females diagnosed with breast, cervical, ovarian, and endometrial cancer to self-reported contraceptive use in a control group of women who had cancers that had no known relationship to hormonal contraceptive use.

The researchers found that women who were either current or previous users of hormonal contraceptives had significantly increased incidence of breast cancer over women who had never used them; incidence was significantly increased regardless of the form of contraceptive used (injectable or oral). Incidence of cervical cancer was also significantly increased in users of injectable contraceptives but not oral contraceptives. However, the researchers found that the incidence of breast cancer and cervical cancer were not significantly increased in women who ceased their use of hormonal contraceptives in the ten years or more prior to the study.

Women who had used injectable contraceptives, exclusively, for five or more years prior to the study had significantly higher incidence of ovarian cancer than women who had never used them. Finally, women who had used oral and/or injectable contraceptives, but not exclusively injectables, had a significantly higher incidence of endometrial cancer. The researchers concluded that incidence of female cancers were similar regardless of how the contraceptive was administered.    


Share this article:

Related Resources

You must be a registered member of Chemotherapy Advisor to post a comment.

Sign Up for Free e-newsletters

Enter Our April Contest

Start the contest today

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Gynecologic Cancer

High-volume Centers Have Higher Gynecologic Cancer Survival

High-volume Centers Have Higher Gynecologic Cancer Survival

Survival advantage of 2.3 to 34.1 months for treatment at highest- versus lowest-volume centers.

BRCA Mutation Risk Underestimated by BRCAPRO Model

BRCA Mutation Risk Underestimated by BRCAPRO Model

More mutations observed than expected at BRCAPRO scores of less than 40%.

FDA Panel Recommends HPV Test That Could Replace Pap

FDA Panel Recommends HPV Test That Could Replace ...

Experts voted 13-0 that Roche's test was safe and effective as first step in cervical cancer screening.